Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 10/20 | 0.46 |
| ▸ | NPC1 | O15118 | 9/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14776733 | 0.80 | KDM4E (0.51) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL436384 | 0.79 | GAA (0.57) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL25180859 | 0.79 | MAPT (0.54) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL15716531 | 0.78 | IKBKB (0.56) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL869242 | 0.78 | GAA (0.51) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL15716993 | 0.76 | IKBKB (0.54) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL5536086 | 0.76 | GAA (0.50) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL272772 | 0.76 | NPC1 (0.50) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL14431592 | 0.76 | GAA (0.54) | GAARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL13407782 | 0.76 | GAA (0.50) | GAARAB9ANPC1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2950153-B1 | ELECTROPHOTOGRAPHIC MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | CANON KK (JP) | 2020-04-15 | — | — | EP | disclosed |
| US-9639009-B2 | Electrophotographic member, process cartridge, and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| EP-2950153-A1 | ELECTROPHOTOGRAPHIC MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | Canon Kabushiki Kaisha (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-20150331341-A1 | ELECTROPHOTOGRAPHIC MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2015-11-19 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015124868-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2015-08-27 | — | — | WO | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | MAP3K1, MAP3K6, MAP3K9 | GAA 1953/4885RAB9A 1302/4885NPC1 3118/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | GAA 4276/4885RAB9A 1766/4885NPC1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.